

MEDIMMUNE INC /DE  
 Form 4  
 June 19, 2007

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 HACKMAN FRANKLIN  
 BARBARA

(Last) (First) (Middle)

ONE MEDIMMUNE WAY

(Street)

GAITHERSBURG, MD 20878

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
 MEDIMMUNE INC /DE [MEDI]

3. Date of Earliest Transaction  
 (Month/Day/Year)  
 06/18/2007

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership Indirect Beneficial Ownership (Instr. 4)		
				(A) or (D)	Code	V	Amount	(D)	Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
--	------------------------------------	--------------------------------------	--	--------------------------------	---	--	---

Edgar Filing: MEDIMMUNE INC /DE - Form 4

Derivative Security			or Disposed of (D) (Instr. 3, 4, and 5)		Date Exercisable	Expiration Date	Title	Amount or Number of Shares
			Code	V (A) (D)				
Stock Option (right to buy)	\$ 24.04	06/18/2007	D	30,000	<u>(1)</u>	06/30/2009	Common Stock	30,000
Stock Option (right to buy)	\$ 47.2	06/18/2007	D	30,000	<u>(2)</u>	06/30/2011	Common Stock	30,000
Stock Option (right to buy)	\$ 26.4	06/18/2007	D	30,000	<u>(3)</u>	06/30/2012	Common Stock	30,000
Stock Option (right to buy)	\$ 35.84	06/18/2007	D	30,000	<u>(4)</u>	06/30/2013	Common Stock	30,000
Stock Option (right to buy)	\$ 23.17	06/18/2007	D	30,000	<u>(5)</u>	06/30/2014	Common Stock	30,000
Stock Option (right to buy)	\$ 27.12	06/18/2007	D	30,000	<u>(6)</u>	06/30/2015	Common Stock	30,000
Stock Option (right to buy)	\$ 27.12	06/18/2007	D	25,000	<u>(7)</u>	06/30/2016	Common Stock	25,000

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
HACKMAN FRANKLIN BARBARA ONE MEDIMMUNE WAY GAITHERSBURG, MD 20878	X			

## Signatures

/s/ William C. Bertrand, Jr.,  
Attorney-in-Fact

06/19/2007

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) This option, which provided for vesting in four equal annual installments beginning on 06/30/2000, was cancelled pursuant to the merger agreement between the issuer and AstraZeneca PLC in exchange for a cash payment of \$33.96, representing the difference between the exercise price of the option and \$58.00 per share.

(2) This option, which provided for vesting in four equal annual installments beginning on 06/30/2002, was cancelled in the merger in exchange for a cash payment of \$10.80 per share, representing the difference between the exercise price of the option and \$58.00 per share.

(3) This option, which provided for vesting in four equal annual installments beginning on 06/30/2003, was cancelled in the merger in exchange for a cash payment of \$31.60 per share, representing the difference between the exercise price of the option and \$58.00 per share.

(4) This option, which provided for vesting in four equal annual installments beginning on 06/30/2004, was cancelled in the merger in exchange for a cash payment of \$22.16 per share, representing the difference between the exercise price of the option and \$58.00 per share.

(5) This option, which provided for vesting in four equal annual installments beginning on 06/30/2005, was cancelled in the merger in exchange for a cash payment of \$34.83 per share, representing the difference between the exercise price of the option and \$58.00 per share.

(6) This option, which provided for vesting in four equal annual installments beginning on 06/30/2006, was cancelled in the merger in exchange for a cash payment of \$30.88 per share, representing the difference between the exercise price of the option and \$58.00 per share.

(7) This option, which provided for vesting in four equal annual installments beginning on 06/30/2007, was cancelled in the merger in exchange for a cash payment of \$30.88 per share, representing the difference between the exercise price of the option and \$58.00 per share.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.